Transplantation
The promise of CAR-T therapy in CLL and challenges in the field
The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents,…
Date: 31st August 2022
T-cell engagers in multiple myeloma: current challenges and future outlooks
Several novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of…
Date: 24th August 2022
CAR-T therapy in AML: challenges and future outlooks
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While…
Date: 10th August 2022
The current state of CAR-T therapy in lymphoma
Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R)…
Date: 5th August 2022
Myeloma treatment updates from EHA 2022
While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years….
Date: 3rd August 2022
Updates in classification and risk stratification in MDS
Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years,…
Date: 27th July 2022
Myeloma 2022: day one highlights
At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety…
Date: 27th July 2022
Immune dysregulation and targeting in MDS
Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in…
Date: 22nd July 2022
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
While the treatment of multiple myeloma has seen several recent advances, challenges still remain when approaching patients with high-risk disease,…
Date: 24th June 2022
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March…
Date: 3rd June 2022
CAR-T and lymphoma treatment in the UK
Lymphoma treatment has seen many recent advances, with CAR-T therapy being a game changer for patients. Several clinical trials investigating…
Date: 27th May 2022
ASH 2021: the future of cell therapies in lymphoma
Cell therapies including chimeric antigen receptor (CAR) T-cell therapy represent novel treatments for patients with lymphoma, especially for those who…
Date: 25th February 2022